Literature DB >> 25197347

Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide.

Yingxia Tan1, Laixi Bi2, Peili Zhang1, Fule Wang1, Feiyan Lin1, Wuhua Ni3, Jianbo Wu1, Lei Jiang1.   

Abstract

Thioredoxin-1 (Trx-1), an important redox regulatory factor, plays a significant role in drug-induced apoptosis. Here we investigated the effects of the Trx-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) on human acute myeloid leukemia cells (AML) and the sensitivity of cells to arsenic trioxide (As2O3, ATO). Treatment of cells with a different concentration of PX-12 for 48 h resulted in growth inhibition, the induction of apoptosis and increased the levels of activated caspase-3 expression in AML cell lines HL-60, NB4, U937 and primary AML cells in a dose-dependent manner. In addition, PX-12 enhanced the sensitivity of U937 cells to ATO. These results suggest the effects of Trx-1 inhibitor PX-12 to induce apoptosis in AML cells and therapeutic potential in AML by enhancing the sensitivity of cells to ATO.

Entities:  

Keywords:  PX-12; acute myeloid leukemia; apoptosis; arsenic trioxide

Mesh:

Substances:

Year:  2014        PMID: 25197347      PMCID: PMC4152037     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  42 in total

Review 1.  Properties and biological activities of thioredoxins.

Authors:  G Powis; W R Montfort
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001

2.  PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis.

Authors:  Bo Ra You; Hye Rim Shin; Woo Hyun Park
Journal:  Int J Oncol       Date:  2013-10-29       Impact factor: 5.650

Review 3.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

Review 4.  The prevalent predicament of relapsed acute myeloid leukemia.

Authors:  Jeffrey Szer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

5.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

6.  Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide.

Authors:  Qin-Shu Shao; Zai-Yuan Ye; Zhi-Qiang Ling; Jin-Jing Ke
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

Review 7.  Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.

Authors:  James L Slack; Samuel Waxman; Guido Tricot; Martin S Tallman; Clara D Bloomfield
Journal:  Oncologist       Date:  2002

Review 8.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

9.  The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.

Authors:  Sarah J Welsh; Ryan R Williams; Anne Birmingham; David J Newman; D Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2003-03       Impact factor: 6.261

Review 10.  Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases.

Authors:  Eiji Yoshihara; So Masaki; Yoshiyuki Matsuo; Zhe Chen; Hai Tian; Junji Yodoi
Journal:  Front Immunol       Date:  2014-01-09       Impact factor: 7.561

View more
  7 in total

1.  ER stress related factor ATF6 and caspase-12 trigger apoptosis in neonatal hypoxic-ischemic encephalopathy.

Authors:  Luran Liu; Chang Liu; Yuting Lu; Lina Liu; Yan Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma.

Authors:  Prahlad V Raninga; Giovanna Di Trapani; Slavica Vuckovic; Maneet Bhatia; Kathryn F Tonissen
Journal:  Oncotarget       Date:  2015-06-20

3.  Thioredoxin-1 Protects Bone Marrow-Derived Mesenchymal Stromal Cells from Hyperoxia-Induced Injury In Vitro.

Authors:  Lei Zhang; Jin Wang; Yan Chen; Lingkong Zeng; Qiong Li; Yalan Liu; Lin Wang
Journal:  Oxid Med Cell Longev       Date:  2018-01-21       Impact factor: 6.543

Review 4.  Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side.

Authors:  Rodrigo Prieto-Bermejo; Marta Romo-González; Alejandro Pérez-Fernández; Carla Ijurko; Ángel Hernández-Hernández
Journal:  J Exp Clin Cancer Res       Date:  2018-06-26

5.  Increased Thioredoxin-1 Expression Promotes Cancer Progression and Predicts Poor Prognosis in Patients with Gastric Cancer.

Authors:  Wenjing Shang; Zhongdong Xie; Fengying Lu; Daoquan Fang; Tianbin Tang; Ruichun Bi; Lingli Chen; Lei Jiang
Journal:  Oxid Med Cell Longev       Date:  2019-02-18       Impact factor: 6.543

Review 6.  Oxidative resistance of leukemic stem cells and oxidative damage to hematopoietic stem cells under pro-oxidative therapy.

Authors:  Yongfeng Chen; Yong Liang; Xingjing Luo; Qiongying Hu
Journal:  Cell Death Dis       Date:  2020-04-27       Impact factor: 8.469

Review 7.  Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants.

Authors:  Aysegul Cort; Tomris Ozben; Luciano Saso; Chiara De Luca; Liudmila Korkina
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.